Adeno-associated viruses (AAVs) have emerged as a leading vector for gene therapies. Platform solutions offer a well-known approach for addressing the inherent complexity, and inconsistent yields often associated with transient AAV production.
In this webinar, we explore the AAViator™ Production Platform, a novel transfection solution for transient AAV production in HEK293 cells. We will discuss studies comparing the AAViator™ Production Platform's performance to commercially available polymer-only and lipid-only transient transfection reagents. Additionally, we will evaluate the platform across various AAV serotypes, transgenes/gene of interest (GOI), and HEK293 cell lineages at small and bench bioreactor scales. Finally, we will examine how this versatile solution can reduce batch costs and costs per dose.
In this webinar, you will learn:
- How the AAViator™ Production Platform can maximize yields across multiple AAV serotypes (AAV5, AAV8, AAV9) and various HEK293-based cell lines.
- How a platform approach can streamline AAV upstream process development by minimizing the need for extensive optimization of transfection reagents and media.
- Methodologies for optimizing key transfection parameters for AAV manufacturing.
- Key learnings for successful scale up of transient AAV processes to bench-scale stirred-tank bioreactors.
- Ways an optimized upstream process can help manage batch costs and costs per dose for scalability and commercial viability
Speakers
Benjamin Ross-Johnsrud
Merck
Senior Scientist - Focused Modality Applications
Benjamin Ross-Johnsrud is a senior scientist in focused modality applications for process solutions at Merck. In his current role, he focuses on analytical development, process development, and automation to establish capabilities in novel modalities. Over his six-year tenure at {hcompamy} and his 13 years in the biopharmaceutical industry, he has held multiple R&D and field applications roles, enjoying both the developing and deploying novel technologies into biopharmaceutical as well as cell and gene therapy unit operations.
John Schiel
Mirus Bio
Senior Product Manager
John Schiel, a senior product manager at Mirus Bio, leads the introduction of innovative transfection and production technology to the cell and gene therapy market. With more than a decade of experience bridging scientific research and product development, he has successfully launched products for both research and cell and gene therapy manufacturing applications spanning multiple scientific disciplines. John holds a Ph.D. from the University of Colorado Medical School and is committed to advancing technologies that enable discoveries and therapeutic development in cell and gene therapy.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
期间:1h
语言:English
场次 1:往期 November 20, 2025
如要继续阅读，请登录或创建帐户。
暂无帐户？